Clinical Trial Materials

Kadimastem and Pluri Enter Cell Therapy Manufacturing Deal

July 20, 2024

PluriCDMO, Pluri's newly launched CDMO division, has been selected by Kadimastem to manufacture two novel cell therapy product candidates.

eXmoor pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities

October 12, 2023

The 65,000-square-foot facility is designed with the capacity and capability to help scale the next generation of CGTs for human trials and beyond.

Vaxxas Opens Manufacturing Facility for Clinical Trials and Commercial Products

June 20, 2023

The new facility also provides a plan for scalable product production processes that can potentially be replicated by Vaxxas domestically and globally.

Aptamer Group and Neuro-Bio Collaborate to Develop Alzheimer’s Disease Diagnostic Test

June 15, 2023

The integration of the binders into a routine lateral flow test will support the clinical and commercial development of rapid diagnostics for Alzheimer’s disease through nasal sampling.

Envisioning Digital Pharma Manufacturing

May 02, 2023

Digital transformation to the Pharma 4.0 paradigm moves forward in process development and clinical and commercial manufacturing.

IRBs Need More Monitoring

February 23, 2023

GAO calls for more oversight of institutional review boards in clinical trials.

Boehringer Ingelheim, 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 13, 2023

It is intended to identify the most prevalent and immunogenic targets in solid tumors by uniquely combining high-diversity target libraries with active machine learning.

Catalent Completes Expansion of Clinical Supply Facility

December 01, 2022

Catalent has completed the expansion of its clinical supply facility located in Shanghai, China.

Pfizer, Merck KGaA, and Immutep Enter into Second Clinical Trial Collaboration Agreement

November 30, 2022

The agreement will see Immutep and Merck KGaA, Darmstadt, Germany jointly fund the INSIGHT-005 study.

CellVax and Theragent Form Manufacturing Pact for Novel Cancer Immunotherapy Drug Candidate

November 17, 2022

CellVax Therapeutics has selected Theragent, a new CDMO, to manufacture clinical trial material for a new Phase II prostate cancer immunotherapy drug candidate.